As Pediatric Nephrologists, we do not do routing therapeutic drug monitoring of MMF, and neither it is available as a part of routine lab test. Current edition of Pediatric Nephrology reviews this topic, and makes us feel that maybe we should be doing more studies on this aspect, and do this in addition to Tacrolimus in Pediatric renal transplantation in the world.
The paper says- ' In terms of short-term efficacy, there is strong evidence that a MPA area under the time-concentration curve of >30 mg × h/L reduces acute rejection episodes early after renal transplantation, and there is evolving evidence that aiming for the same exposure over the long term may be a viable strategy to reduce the formation of donor-specific antibodies.'
Link to the Original Review
Image Source
The paper says- ' In terms of short-term efficacy, there is strong evidence that a MPA area under the time-concentration curve of >30 mg × h/L reduces acute rejection episodes early after renal transplantation, and there is evolving evidence that aiming for the same exposure over the long term may be a viable strategy to reduce the formation of donor-specific antibodies.'
Link to the Original Review
Image Source
No comments:
Post a Comment